Company Overview
Skye Bioscience, Inc. operates as a clinical-stage biotechnology company dedicated to developing molecules that modulate G-protein-coupled receptors, specifically targeting the treatment of obesity, overweight conditions, and metabolic diseases. The company functions within the broader healthcare sector and the specific industry of biotechnology, a domain characterized by high research and development costs and significant regulatory hurdles for product approval. Its current operational scale is defined by a market capitalization of $19.26M and an employee count of 12 individuals. The combination of a market cap under $20 million and a lack of reported annual revenue indicates that the company is in an early-stage development phase, relying on future clinical trial success rather than current commercial sales to generate value.
Financial Health
The company reports a Net Income of $-55,924,816 and an EBITDA of $-57,440,212, while Revenue remains N/A for the trailing twelve months. The substantial gap between the reported net income and EBITDA, alongside the absence of revenue, reveals a cost structure dominated by research and development expenditures and general administrative costs rather than commercial operations. Free cash flow stands at $-22,953,560, indicating that the company is burning cash at a significant rate and lacks immediate financial flexibility to fund operations without external capital injection. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which is typical for clinical-stage biotechnology firms that have not yet generated product sales to derive profitability from their pipeline. The balance sheet shows a cash position of $25.74M against total debt of $273,646, resulting in a debt-to-equity ratio of 1.37, suggesting a leveraged position relative to equity but one supported by a significant cash reserve. The current ratio is 3.30, indicating a conservative short-term liquidity profile where current assets significantly exceed current liabilities, providing a buffer against immediate financial obligations. Return on Equity is -126.8% and Return on Assets is -71.9%, metrics that reflect the company's current inability to generate positive returns on the capital invested by shareholders or held in assets due to the pre-commercial nature of its business model.
Valuation Assessment
The P/E Ratio (TTM) is listed as N/A due to negative earnings, while the Forward P/E is -0.54, a figure that implies an expectation of continued negative earnings or a valuation model based on pre-profitability metrics rather than traditional earnings multiples. The Price to Book ratio is 0.96, indicating that the market values the company at 96% of its book value, which suggests the stock is trading near its net asset value rather than commanding a significant premium for its intellectual property or pipeline potential. The Price to Sales ratio is N/A because there are no reported sales, and the EV/EBITDA stands at 0.11, an extremely low multiple that reflects the company's negative earnings and lack of a traditional operating profit base for valuation comparison. The 52-week high is $5.75 and the 52-week low is $0.57, meaning the stock has experienced substantial volatility within this range over the past year. The Beta is 2.86, which signifies that the stock's price volatility is nearly three times that of the broader market, exposing investors to significantly higher swings in share price compared to large-cap equities.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, reflecting the company's status as a pre-revenue entity with no historical earnings data to compare against for growth calculations. Consequently, there is no revenue growth trajectory to analyze against earnings growth, as the company has not yet transitioned from research phases to commercial sales. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning it does not distribute cash to shareholders but instead retains all available capital, including its $25.74M cash reserve, to fund ongoing development activities. This reinvestment strategy is standard for clinical-stage biotechnology firms, where capital is directed toward advancing the nimacimab candidate and conducting clinical trials rather than providing income to investors. The overall growth and income profile is defined by the absence of current financial returns and a reliance on future clinical milestones to potentially unlock commercial revenue and profitability.